Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Reply: Genotype-phenotype correlations in SCN8A-related epilepsy: a cohort study of Chinese children in southern China

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Genome-wide association study of febrile seizures implicates fever response and neuronal excitability genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Elucidating the relationship between migraine risk and brain structure using genetic data

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The PACAP pathway is independent of CGRP in mouse models of migraine: possible new drug target?

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy in women with MS: Impact on long-term disability accrual in a nationwide Danish Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

In the past decade, changes have occurred in the spectrum of multiple sclerosis courses. The natural history of multiple sclerosis appears milder from the first sign of demyelinating disease to the progressive course, probably as a result of an interplay between several factors including changes in the diagnostic criteria, changes in the epidemiology of multiple sclerosis, impact of early and appropriate disease-modifying treatment and improvement of the general state of health in the population. It has been suggested to regard incidental findings of demyelinating lesions in MRI in individuals without any history of clinical symptoms consistent with neurological dysfunction, so-called radiological isolated syndrome, as the initial course of multiple sclerosis. New diagnostic criteria have enabled the multiple sclerosis diagnosis in many patients at the first clinical demyelinating event, clinically isolated syndrome. The remaining patients with clinically isolated syndrome have a more benign prognosis, and for relapsing-remitting multiple sclerosis, the prognosis has become more favourable. Reduced disease activity in patients with relapsing-remitting multiple sclerosis can partly be ascribed to more efficacious new disease-modifying therapies but decrease in disease activity has also be seen in placebo-treated patients in clinical trials. This may be explained by several factors: change in the diagnostic criteria, more explicit inclusion criteria, exclusion of high-risk patients e.g. patients with co-morbidities, and more rigorous definitions of relapses and disease worsening. However, these factors also make the disease course in patients treated with disease-modifying therapies seem more favourable. In addition, change in the therapeutic target to stable disease (no evidence of disease activity = no relapses, no disease worsening and no MRI activity) could by itself change the course in relapsing-remitting multiple sclerosis. The effectiveness of disease-modifying drugs has reduced the transition from relapsing-remitting to secondary progressive multiple sclerosis. The concept of progressive multiple sclerosis has also evolved from two very distinct categories (primary progressive and secondary progressive multiple sclerosis) to a unified category of progressive multiple sclerosis, which can then be split into the categories of active or inactive. Also, an increasing tendency to treat progressive multiple sclerosis with disease-modifying therapies may have contributed to change the course in progressive multiple sclerosis. In conclusion, during the past decade the entire course of multiple sclerosis from the first sign of a demyelinating disorder through the progressive course appears to be milder due to a complex interplay of several factors.

Original languageEnglish
JournalBrain
Volume143
Issue number9
Pages (from-to)2637-2652
Number of pages16
ISSN0006-8950
DOIs
Publication statusPublished - 1 Sep 2020

    Research areas

  • multiple sclerosis, clinically isolated syndrome, epidemiology, imaging, biomarkers

ID: 61519730